Methylphenidate
Methylphenidate is a central nervous system (CNS) stimulant used to treat attention deficit hyperactivity disorder (ADHD) in children, teens and adults, and, in some oral products, narcolepsy.
🧬 Where this information comes from Click to expand
The clinical label records used on this page are FDA-filed Structured Product Labeling (SPL) retrieved through openFDA. We identified 94 clinical label sets within the page’s selected clinical scope after exact ingredient or ingredient-combination matching and applicable route/form matching. Forms, routes, brands, labelers, strengths, and NDC product-record counts are built separately from matching FDA National Drug Code Directory records. The linked DailyMed document is a representative official source for verification, not the page’s only clinical source. View the linked label on DailyMed →
Methylphenidate is a stimulant for ADHD (and, in some products, narcolepsy) that is thought to block the recycling of dopamine and norepinephrine and boost their release; it is a usual first choice for ADHD, in use since the mid-1950s and available generically. Most people tolerate it well, mainly noticing a smaller appetite and trouble sleeping. The boxed warning is for abuse, misuse and addiction, which can lead to overdose and death, so keep it locked up and never share it. It also raises heart rate and blood pressure, so expect both to be checked at follow-up visits, plus height and weight in children.
Clinical pearls
- Swallow extended-release tablets such as Concerta whole, and never crush or chew them.
- Jornay PM breaks the usual morning pattern, since it is taken in the evening to work through the next day.
- Tell your surgical team you take it, because it should be skipped on surgery day with certain anesthetics.
- Never combine it with an MAO inhibitor antidepressant, or within two weeks of stopping one, because blood pressure can spike dangerously.
⚠️ FDA Boxed Warning — the FDA’s strongest safety alert ▾
Methylphenidate has a high potential for abuse and misuse, which can lead to addiction. Misuse can cause overdose and death. The risk is higher with larger doses or when it is snorted or injected.
Your prescriber should assess your risk before you start and keep checking during treatment. Store it safely, preferably locked up. Never share it, and dispose of unused medicine properly. Watch for signs of misuse or addiction.
Patient information guide A plain-language walkthrough of Methylphenidate, written from its FDA label.
What Methylphenidate is used for
▾
Methylphenidate is used for the following, depending on the product:
- ADHD in children, teens and adults, with age ranges that vary by product (for example, Relexxii for adults up to 65 and children 6 and older; Cotempla XR-ODT for ages 6 to 17).
- Methylphenidate hydrochloride extended-release capsules (LA) and Ritalin LA for ADHD in children 6 to 12.
- Methylphenidate hydrochloride CD capsules for ADHD in children 6 to 15.
- Daytrana and methylphenidate transdermal system (patches) for ADHD in ages 6 to 17.
- Narcolepsy with certain methylphenidate tablets.
- Methylphenidate oral solution and chewable tablets for attention deficit disorders in children, as part of a total treatment program.
How Methylphenidate works
▾
Methylphenidate is a CNS stimulant. It is thought to block the reuptake of norepinephrine and dopamine into nerve cells and to increase their release. How this leads to benefit in ADHD is not known.
Methylphenidate dosage
▾
Dosing depends on the product, so follow your prescriber and your product’s label.
- Many extended-release tablets and capsules are taken once daily in the morning.
- Concerta and similar extended-release tablets are swallowed whole, not chewed, divided or crushed.
- Some capsules may be opened and sprinkled on applesauce.
- Jornay PM is taken in the evening.
- Quillivant is shaken well before each dose.
- Daytrana and the methylphenidate patch are worn on the hip, applied about 2 hours before an effect is needed and removed after 9 hours.
Doses are usually adjusted weekly. Do not switch between methylphenidate products on your own.
Dosing details from the FDA-approved label
From the Methylphenidate prescribing information (“Dosage and Administration”). Doses are set by your prescriber for your product, condition, kidney function and age — never change a dose on your own.
- Patients new to or converting from another formulation of methylphenidate (Daytrana / Methylphenidate Transdermal System)
- Recommended starting dose is 10 mg
- Apply to the hip area (alternating sites) 2 hours before an effect is needed and remove 9 hours after application
- Titration if response is not maximized: Week 1 12.5 cm2 (10 mg/9 hours, 1.1 mg/hr)
- Week 2 18.75 cm2 (15 mg/9 hours, 1.6 mg/hr)
- Week 3 25 cm2 (20 mg/9 hours, 2.2 mg/hr)
- Week 4 37.5 cm2 (30 mg/9 hours, 3.3 mg
- May be removed earlier than 9 hours if a shorter duration of effect is desired or late day side effects appear; dose titrated to effect and individualized
Read the label’s full dosing text
2 DOSAGE AND ADMINISTRATION Prior to initiating methylphenidate hydrochloride extended-release tablets treatment assess for ( 2.1 ): the presence of cardiac disease for family history of tics or Tourette’ syndrome and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome Administer once daily in the morning with or without food. Swallow whole with liquids; do not chew, divide, or crush. ( 2.2 ) Recommended dosage in pediatric patients 6 to 17 years of age new to methylphenidate: starting dosage is18 mg once daily. May be increased weekly in 18 mg increments. Maximum dosage for pediatric patients ( 2.3 ): 6 to 12 years: 54 mg once daily 13 to 17 years: 72 mg once daily Recommended dosage in adults (up to 65 years of age) new to methylphenidate: starting dosage is 18 mg or 36 mg once daily. May be increased weekly in 18 mg increments, up to 72 mg once daily. ( 2.3 ) Patients currently using immediate-release methylphenidate: starting methylphenidate hydrochloride extended-release tablets dosage is based on current dosage regimen. ( 2.4 ) 2.1 Pretreatment Screening Prior to treating patients with methylphenidate hydrochloride extended-release tablets, assess: For the presence of cardiac disease (e.g., perform a careful history, family history of sudden death or ventricular arrhythmia, and physical exam) [see Warnings and Precautions ( 5.2) ]. The family history for tics or Tourette’ syndrome and clinically evaluate patients for motor or verbal tics or Tourette’s syndrome [see Warnings and Precautions ( 5.11 )]. 2.2 Important Administration Instructions Administer methylphenidate hydrochloride extended-release tablets orally once daily in the morning with or without food. Swallow methylphenidate hydrochloride extended-release tablets whole with liquids. Do not split, crush, or chew the extended-release tablets because doing so will compromise the extended-release characteristics of methylphenidate hydrochloride extended-release tablets and may compromise the effectiveness or safety of methylphenidate hydrochloride extended-release tablets. 2.3 Recommended Methylphenidate Hydrochloride Extended-Release Tablets Dosage in Patients New to Methylphenidate See Table 1 for the recommended once-daily dosage of methylphenidate hydrochloride extended-release tablets in patients who were not taking a methylphenidate product.
Excerpted — the section continues on the label. Read the full Dosage and Administration section on DailyMed →
Methylphenidate side effects
▾
Common side effects include:
Common side effects
- Decreased appetite
- Headache
- Dry mouth
- Nausea
- Trouble sleeping (insomnia)
- Anxiety
- Dizziness
- Upper stomach pain (more common in children and teens)
- Irritability
- Weight loss
- Sweating
When to get medical help
- Get help right away for chest pain, fainting, or a very fast or irregular heartbeat, especially if you have heart problems. Sudden death has been reported in people with serious heart disease.
- Call your doctor about new hallucinations, delusional thinking, mania, or worsening behavior or thinking problems.
- Seek emergency care for a seizure.
- Seek immediate medical attention for erections that are painful or last abnormally long.
- Tell your doctor if your fingers or toes change color, feel numb or cool, or develop sores.
- Call your doctor if you notice signs of misuse or addiction, or new or worsening tics.
- With the patch, report lasting loss of skin color or a strong skin reaction that spreads or does not improve within 48 hours.
Call your doctor for heart symptoms, mood or thinking changes, seizures, painful prolonged erections, or color changes in fingers or toes.
Methylphenidate warnings and precautions
▾
- Abuse, misuse and addiction (boxed warning) can lead to overdose and death.
- Sudden death has been reported in people with serious heart disease. Avoid use with known serious heart problems.
- It can raise blood pressure and heart rate, so these should be monitored.
- It can cause or worsen psychosis or mania.
- It may lower the seizure threshold.
- It can cause priapism (prolonged, painful erections) and Raynaud’s phenomenon (poor circulation in fingers and toes).
- It can slow growth in children.
- It can worsen tics or Tourette’s syndrome.
- It can raise eye pressure and affect glaucoma.
- The patch can cause lasting skin color loss and skin sensitization, and heat on the patch increases absorption.
Methylphenidate interactions
▾
Tell your prescriber about every medicine you take. Key interactions include:
- MAO inhibitors: can cause a dangerous blood pressure surge (hypertensive crisis). Do not combine, or use within 14 days of stopping one.
- Blood pressure medicines: methylphenidate may make them work less well.
- Halogenated anesthetics: may cause sudden blood pressure and heart rate jumps during surgery.
- Risperidone: movement-related side effects may increase when doses change.
Interactions listed in the FDA-approved label
From the Methylphenidate prescribing information (“Drug Interactions”): what the manufacturer studied or reported to the FDA.
- Monoamine Oxidase Inhibitors (MAOIs): Concomitant use of MAOIs and CNS stimulants can cause hypertensive crisis; potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Concomitant use with MAOIs or within 14 days after discontinuing an MAOI is contraindicated.
- Antihypertensive Drugs: Methylphenidate may decrease effectiveness of drugs used to treat hypertension. Increase monitoring for blood pressure and adjust the dosage of the antihypertensive drug, as needed.
- Halogenated Anesthetics: Concomitant use may increase the risk of sudden blood pressure and heart rate increase during surgery. Avoid use of methylphenidate in patients being treated with anesthetics on the day of surgery.
- Risperidone: The risk of risperidone-associated extrapyramidal symptoms may increase when there is a change in the methylphenidate or risperidone dosage. Monitor for signs of extrapyramidal symptoms.
Read the label’s full interactions text
7 DRUG INTERACTIONS Table 6 describes clinically significant drug interactions with methylphenidate hydrochloride extended-release tablets. Table 6: Clinically Significant Drug Interactions Monoamine Oxidase Inhibitors Prevention or Management Concomitant use of CNS stimulants, including methylphenidate hydrochloride extended-release tablets, with MAOIs or within 14 days after discontinuing an MAOI is contraindicated [see Contraindications (4) ] . Mechanism and Clinical Effect(s) Concomitant use of MAOIs and CNS stimulants, including methylphenidate hydrochloride extended-release tablets, can cause hypertensive crisis. Potential outcomes include death, stroke, myocardial infarction, aortic dissection, ophthalmological complications, eclampsia, pulmonary edema, and renal failure. Antihypertensive Drugs Prevention or Management Increase monitoring for blood pressure and adjust the dosage of the antihypertensive drug, as needed. Mechanism and Clinical Effect(s) Methylphenidate hydrochloride extended-release tablets may decrease effectiveness of drugs used to treat hypertension [see Warnings and Precautions (5.3) ] . Halogenated Anesthetics Prevention or Management Avoid use of methylphenidate hydrochloride extended-release tablets in patients being treated with anesthetics on the day of surgery. Mechanism and Clinical Effect(s) Concomitant use of halogenated anesthetics and methylphenidate hydrochloride extended-release tablets may increase the risk of sudden blood pressure and heart rate increase during surgery. Risperidone Prevention or Management Monitor for signs of extrapyramidal symptoms. Mechanism and Clinical Effect(s) The risk of risperidone-associated extrapyramidal symptoms may increase in patients taking concomitant methylphenidate hydrochloride extended-release tablets when there is a change in the methylphenidate hydrochloride extended-release tablets or risperidone dosage. Antihypertensive drugs : Monitor blood pressure.
Excerpted — the section continues on the label. Read the full Drug Interactions section on DailyMed →
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before taking Methylphenidate
▾
- Do not use if you are allergic to methylphenidate or are taking or recently stopped an MAO inhibitor.
- Tell your doctor about heart disease, high blood pressure, psychiatric illness, seizures, tics, glaucoma, or past substance misuse.
- Not recommended in children under 6.
- Safety is not established in people over 65 for some products.
- Pregnancy: findings are inconsistent, so discuss risks and benefits with your doctor.
- Breastfeeding: methylphenidate passes into breast milk, so the infant should be monitored.
Methylphenidate overdose
▾
Too much methylphenidate can cause a fast or abnormal heartbeat, high or low blood pressure, agitation, confusion, hallucinations, seizures, dangerously high body temperature and muscle breakdown. Heart attack, stroke and coma are possible. Call Poison Help at 1-800-222-1222 or seek emergency care. For the patch, remove all patches right away and clean off adhesive.
What Methylphenidate does in the body
▾
Methylphenidate is a mix of two forms, and the d-threo form is more active. It blocks norepinephrine and dopamine reuptake and increases their release. A study of the related drug dexmethylphenidate showed no heart-rhythm (QT) effect of clinical concern.
How your body processes Methylphenidate
▾
Methylphenidate is readily absorbed by mouth. Concerta-type extended-release tablets rise quickly to a first peak at about 1 hour, then climb gradually, reaching peak levels in about 6 to 10 hours. The half-life is roughly 3.5 hours, and the drug does not build up with once-daily use. It is broken down mainly to an inactive metabolite, PPAA.
How to store Methylphenidate
▾
Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) . Protect from humidity.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
Supplements & herbs that interact with Methylphenidate
85 supplements and herbal products have documented interactions with Methylphenidate in the licensed clinical database we use. Most are manageable — but your pharmacist should know about everything you take, including vitamins and herbals.
- Major · 6
- Moderate · 64
- Minor · 15
Educational information from a licensed clinical database (Natural Medicines) — see our data sources & update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Methylphenidate: pharmacist answers to common questions
Quick, plain-English answers to the questions patients ask most about Methylphenidate — the kind of thing our pharmacy team would talk through with you at the counter.
What is methylphenidate used for?
▾
How should I take it?
▾
What side effects should I expect?
▾
When should I call my doctor right away?
▾
Is there anything I shouldn’t mix it with?
▾
Can it be habit-forming?
▾
Is Methylphenidate available over the counter?
▾
Is Methylphenidate a controlled substance?
▾
When was Methylphenidate first available?
▾
Who makes Methylphenidate?
▾
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI →
More about Methylphenidate on HelloPharmacist
Methylphenidate forms and strengths (how it comes)
Methylphenidate is available in 10 forms. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Methylphenidate inactive ingredients by manufacturer.
Extended-release capsule
How this form is used
- Methylphenidate Hydrochloride (LA) capsules are used for ADHD in children 6 to 12 years old.
- Methylphenidate hydrochloride CD capsules are used for ADHD in children 6 to 15 years old.
- Methylphenidate Hydrochloride (LA) capsules are taken once daily in the morning. They may be swallowed whole or opened and sprinkled on applesauce, and should not be crushed, chewed or divided.
Show 1 more strength Show fewer strengths
Extended-release tablet
How this form is used
- Relexxii is used for ADHD in adults up to age 65 and children 6 and older.
- Concerta is taken once daily in the morning, with or without food.
- Concerta tablets should be swallowed whole with liquids, not chewed, divided or crushed.
Tablet
Oral solution
How this form is used
- Methylphenidate HCl oral solution is used for attention deficit disorders in children as part of a total treatment program.
Chewable tablet
How this form is used
- Methylphenidate hydrochloride chewable tablets are used for attention deficit disorders in children as part of a total treatment program.
Skin patch
Show 11 more strengths Show fewer strengths
Capsule
How this form is used
- Jornay PM is taken only in the evening, and the timing may be adjusted by your prescriber.
- Jornay PM should be taken consistently with or without food.
- Jornay PM capsules may be swallowed whole or opened and sprinkled on applesauce.
Extended-release chewable tablet
Extended-release oral suspension
How this form is used
- Quillivant is shaken vigorously for at least 10 seconds before each dose.
- Quillivant is given once daily in the morning, with or without food.
Orally disintegrating tablet
How this form is used
- Cotempla XR-ODT is used for ADHD in children and teens 6 to 17 years old.
Methylphenidate on the U.S. market: products, makers and brands
How Methylphenidate appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
43 companies list 246 Methylphenidate product records with the FDA, mostly as extended-release capsule, extended-release tablet, tablet; the earliest marketing or approval year on record is 1955. Brand names on the directory include Adhansia XR, Aptensio XR, Concerta and 13 more; the rest are generics.
FDA-listed product records by dose form (tablet variants merged) — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
Also listed with the FDA, not a patient dose form: Powder (27) — bulk drug substance sold to compounders/manufacturers and multi-item kits. These aren’t counted in the dose-form total above.
Share of FDA-listed product records by manufacturer — FDA National Drug Code Directory. Record counts are not sales or prescription volume.
How widely Methylphenidate is used (Medicaid data)
A general measure of how commonly Methylphenidate is prescribed, based on Medicaid — one of the largest public drug programs. The figure below is prescriptions filled in Q1–Q4 2025, summed across every form and brand of the drug.
Think of this as a proxy for how widely Methylphenidate is used, drawn from freely available public data. Medicaid is just one program — these numbers don’t include Medicare, other government coverage, or commercial and cash-pay prescriptions, so real-world use is higher than what’s shown here.
How commonly is Methylphenidate prescribed? Of the 1,601 medications we measure, Methylphenidate ranks #35 by Medicaid prescriptions — more than 98% of them.
Utilization by Methylphenidate product
Pick a product to see its own Medicaid numbers. Each chip is one clinical product — a specific strength & dosage form as defined by RxNorm — with brand-name and generic versions combined.
24 HR methylphenidate hydrochloride 36 MG Extended Release Oral Tablet Most dispensed
Summed across the 9 of 24 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091185
24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet
Summed across the 6 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091170
24 HR methylphenidate hydrochloride 18 MG Extended Release Oral Tablet
Summed across the 6 of 27 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091155
methylphenidate hydrochloride 10 MG Oral Tablet
Summed across the 10 of 40 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091150
24 HR methylphenidate hydrochloride 54 MG Extended Release Oral Tablet
Summed across the 6 of 25 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091210
methylphenidate hydrochloride 5 MG Oral Tablet
Summed across the 10 of 38 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091497
methylphenidate hydrochloride 20 MG Oral Tablet
Summed across the 11 of 44 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091392
24 HR methylphenidate hydrochloride 5 MG/ML Extended Release Suspension
Summed across the 4 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1312583
24 HR methylphenidate hydrochloride 20 MG Chewable Extended Release Oral Tablet
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1727443
30/70 Release 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule
Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806187
8 HR methylphenidate hydrochloride 20 MG Extended Release Oral Tablet
Summed across the 3 of 9 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091225
30/70 Release 24 HR methylphenidate hydrochloride 10 MG Extended Release Oral Capsule
Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806181
methylphenidate hydrochloride 1 MG/ML Oral Solution
Summed across the 4 of 19 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091341
50/50 Release 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule
Summed across the 5 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806177
Evening Dosing 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168857
24 HR methylphenidate hydrochloride 30 MG Chewable Extended Release Oral Tablet
Summed across the 1 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1734928
Evening Dosing 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168868
8 HR methylphenidate hydrochloride 10 MG Extended Release Oral Tablet
Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091145
30/70 Release 24 HR methylphenidate hydrochloride 30 MG Extended Release Oral Capsule
Summed across the 4 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806189
Evening Dosing 24 HR methylphenidate hydrochloride 80 MG Extended Release Oral Capsule
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168861
50/50 Release 24 HR methylphenidate hydrochloride 30 MG Extended Release Oral Capsule
Summed across the 6 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806179
30/70 Release 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule
Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806191
50/50 Release 24 HR methylphenidate hydrochloride 10 MG Extended Release Oral Capsule
Summed across the 5 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806195
BX Rating 24 HR methylphenidate hydrochloride 18 MG Extended Release Oral Tablet
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001564
24 HR methylphenidate hydrochloride 40 MG Chewable Extended Release Oral Tablet
Summed across the 1 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1734951
Evening Dosing 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168866
BX Rating 24 HR methylphenidate hydrochloride 27 MG Extended Release Oral Tablet
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001565
Evening Dosing 24 HR methylphenidate hydrochloride 100 MG Extended Release Oral Capsule
Summed across the 1 of 1 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2168864
methylphenidate hydrochloride 2 MG/ML Oral Solution
Summed across the 4 of 17 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091133
BX Rating 24 HR methylphenidate hydrochloride 36 MG Extended Release Oral Tablet
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001566
50/50 Release 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule
Summed across the 6 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806183
BX Rating 24 HR methylphenidate hydrochloride 54 MG Extended Release Oral Tablet
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2001568
30/70 Release 24 HR methylphenidate hydrochloride 50 MG Extended Release Oral Capsule
Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806193
methylphenidate hydrochloride 5 MG Chewable Tablet
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091322
30/70 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule
Summed across the 3 of 5 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806197
24 HR methylphenidate hydrochloride 72 MG Extended Release Oral Tablet
Summed across the 4 of 8 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1995461
methylphenidate hydrochloride 10 MG Chewable Tablet
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091152
methylphenidate hydrochloride 2.5 MG Chewable Tablet
Summed across the 2 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1091389
24 HR methylphenidate hydrochloride 45 MG Extended Release Oral Tablet
Summed across the 2 of 4 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2605798
methylphenidate 25.9 MG Disintegrating Oral Tablet
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926849
methylphenidate 17.3 MG Disintegrating Oral Tablet
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926840
9 HR methylphenidate 1.11 MG/HR Transdermal System
Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753436
9 HR methylphenidate 1.67 MG/HR Transdermal System
Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753438
9 HR methylphenidate 2.22 MG/HR Transdermal System
Summed across the 3 of 7 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753440
methylphenidate 8.6 MG Disintegrating Oral Tablet
Summed across the 1 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1926853
40/60 Release 24 HR methylphenidate hydrochloride 50 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806204
24 HR methylphenidate hydrochloride 63 MG Extended Release Oral Tablet
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 2605796
9 HR methylphenidate 3.33 MG/HR Transdermal System
Summed across the 3 of 6 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 753441
40/60 Release 24 HR methylphenidate hydrochloride 30 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806206
50/50 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule
Summed across the 2 of 3 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806185
40/60 Release 24 HR methylphenidate hydrochloride 40 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806210
40/60 Release 24 HR methylphenidate hydrochloride 20 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806202
40/60 Release 24 HR methylphenidate hydrochloride 15 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1648183
40/60 Release 24 HR methylphenidate hydrochloride 10 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806200
40/60 Release 24 HR methylphenidate hydrochloride 60 MG Extended Release Oral Capsule
Summed across the 2 of 2 listed NDC products with Medicaid activity — every brand and generic of this exact strength & form. RxNorm 1806208
Shares are of the Medicaid prescriptions shown here. Product grouping follows RxNorm (the National Library of Medicine’s drug terminology), so “one product” means one strength & dosage form regardless of manufacturer. Dollar figures are gross Medicaid reimbursement before mandatory rebates — rebates (often large, especially for brand-name drugs) are confidential, so actual net cost to Medicaid is lower than shown.
Source: Medicaid State Drug Utilization Data (CMS), aggregated by generic ingredient — summed across every NDC (all brands, strengths, salt forms and dosage forms) of Methylphenidate, and across all states and both fee-for-service and managed-care claims. A general popularity signal; it excludes Medicare, commercial insurance and cash prescriptions, so it is not total U.S. use. Based on the 177 of 448 listed Methylphenidate NDCs with Medicaid activity.
Compare Methylphenidate products
A representative set of FDA-listed product records for Methylphenidate — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Capsule | ||||
| 20 mg | Oral | Ironshore Pharmaceuticals Inc. | NDA | View NDC → |
| 40 mg | Oral | Ironshore Pharmaceuticals Inc. | NDA | View NDC → |
| 60 mg | Oral | Ironshore Pharmaceuticals Inc. | NDA | View NDC → |
| 80 mg | Oral | Ironshore Pharmaceuticals Inc. | NDA | View NDC → |
| 💊Chewable tablet | ||||
| 10 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 2.5 mg | Oral | Camber Pharmaceuticals Inc. | ANDA | View NDC → |
| 5 mg | Oral | Camber Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | Camber Pharmaceuticals Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 5 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 10 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Rising Pharma Holdings, Inc. | ANDA | View NDC → |
| 2.5 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 💊Extended-release capsule | ||||
| 10 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 15 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 30 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 20 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 30 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 40 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 10 mg | Oral | Aytu BioPharma, Inc. | NDA | View NDC → |
| 20 mg | Oral | Aytu BioPharma, Inc. | NDA | View NDC → |
| 30 mg | Oral | Aytu BioPharma, Inc. | NDA | View NDC → |
| 40 mg | Oral | Aytu BioPharma, Inc. | NDA | View NDC → |
| 10 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| 20 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| 30 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| 40 mg | Oral | Dr. Reddy's Laboratories Inc | ANDA | View NDC → |
| 10 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 20 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 30 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 40 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 10 mg | Oral | Lannett Company, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 20 mg | Oral | Lannett Company, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 30 mg | Oral | Lannett Company, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 40 mg | Oral | Lannett Company, Inc. | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg | Oral | Lannett Company, LLC | NDA | View NDC → |
| 20 mg | Oral | Lannett Company, LLC | NDA | View NDC → |
| 30 mg | Oral | Lannett Company, LLC | NDA | View NDC → |
| 40 mg | Oral | Lannett Company, LLC | NDA | View NDC → |
| 10 mg | Oral | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
| 20 mg | Oral | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
| 30 mg | Oral | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
| 40 mg | Oral | Novartis Pharmaceuticals Corporation | NDA | View NDC → |
| 10 mg | Oral | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 15 mg | Oral | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 20 mg | Oral | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 30 mg | Oral | Rhodes Pharmaceuticals LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg | Oral | Sandoz Inc × 2 listings | NDA AUTHORIZED GENERIC | View NDC → |
| 20 mg | Oral | Sandoz Inc × 2 listings | NDA AUTHORIZED GENERIC | View NDC → |
| 10 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 20 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 30 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 40 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 💊Extended-release chewable tablet | ||||
| 20 mg | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 30 mg | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 40 mg | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 💊Extended-release oral suspension | ||||
| 300 mg/60 mL | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 600 mg/120 mL | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 750 mg/150 mL | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 900 mg/180 mL | Oral | NextWave Pharmaceuticals, Inc | NDA | View NDC → |
| 💊Extended-release tablet | ||||
| 18 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 27 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 36 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 54 mg | Oral | Actavis Pharma, Inc. | ANDA | View NDC → |
| 18 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 27 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 36 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 54 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 27 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 36 mg | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 18 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 27 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 36 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 54 mg | Oral | Camber Pharmaceuticals, Inc. | ANDA | View NDC → |
| 36 mg | Oral | Dr.Reddys Laboratories Inc | ANDA | View NDC → |
| 10 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 18 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 27 mg | Oral | Golden State Medical Supply, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 20 mg | Oral | Granules Pharmaceuticals Inc. | ANDA | View NDC → |
| 18 mg | Oral | Janssen Pharmaceuticals, Inc. | NDA | View NDC → |
| 27 mg | Oral | Janssen Pharmaceuticals, Inc. | NDA | View NDC → |
| 36 mg | Oral | Janssen Pharmaceuticals, Inc. | NDA | View NDC → |
| 54 mg | Oral | Janssen Pharmaceuticals, Inc. | NDA | View NDC → |
| 18 mg | Oral | Lannett Company, Inc. × 2 listings | ANDA | View NDC → |
| 27 mg | Oral | Lannett Company, Inc. × 2 listings | ANDA | View NDC → |
| 72 mg | Oral | Northstar Rx LLC | ANDA | View NDC → |
| 10 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 20 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 27 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 36 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 72 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 18 mg | Oral | Trigen Laboratories, LLC | ANDA | View NDC → |
| 27 mg | Oral | Trigen Laboratories, LLC | ANDA | View NDC → |
| 36 mg | Oral | Trigen Laboratories, LLC | ANDA | View NDC → |
| 45 mg | Oral | Trigen Laboratories, LLC | NDA AUTHORIZED GENERIC | View NDC → |
| 18 mg | Oral | Vertical Pharmaceuticals, LLC | NDA | View NDC → |
| 27 mg | Oral | Vertical Pharmaceuticals, LLC | NDA | View NDC → |
| 36 mg | Oral | Vertical Pharmaceuticals, LLC | NDA | View NDC → |
| 45 mg | Oral | Vertical Pharmaceuticals, LLC | NDA | View NDC → |
| 18 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 27 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 36 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 54 mg | Oral | XLCare Pharmaceuticals, Inc. | ANDA | View NDC → |
| 💊Orally disintegrating tablet | ||||
| 8.6 mg | Oral | Neos Therapeutics, LP | NDA AUTHORIZED GENERIC | View NDC → |
| 17.3 mg | Oral | Neos Therapeutics, LP | NDA AUTHORIZED GENERIC | View NDC → |
| 25.9 mg | Oral | Neos Therapeutics, LP | NDA AUTHORIZED GENERIC | View NDC → |
| 8.6 mg | Oral | Neos Therapeutics Brands, LLC | NDA | View NDC → |
| 17.3 mg | Oral | Neos Therapeutics Brands, LLC | NDA | View NDC → |
| 25.9 mg | Oral | Neos Therapeutics Brands, LLC | NDA | View NDC → |
| 💊Oral solution | ||||
| 5 mg/5 mL | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Ascent Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Ascent Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Bryant Ranch Prepack × 3 listings | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Bryant Ranch Prepack | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Cranbury Pharmaceuticals, LLC | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Cranbury Pharmaceuticals, LLC | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Eywa Pharma Inc | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Eywa Pharma Inc | ANDA | View NDC → |
| 5 mg/5 mL | Oral | KVK-Tech, Inc. | ANDA | View NDC → |
| 10 mg/5 mL | Oral | KVK-Tech, Inc. | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Patrin Pharma, Inc. | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Patrin Pharma, Inc. | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Quagen Pharmaceuticals Llc | ANDA | View NDC → |
| 10 mg/5 mL | Oral | Quagen Pharmaceuticals Llc | ANDA | View NDC → |
| 5 mg/5 mL | Oral | Shionogi Inc. | NDA | View NDC → |
| 10 mg/5 mL | Oral | Shionogi Inc. | NDA | View NDC → |
| 💊Skin patch | ||||
| METHYLPHENIDATE 1.1 mg/h | Transdermal | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| METHYLPHENIDATE 1.6 mg/h | Transdermal | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| METHYLPHENIDATE 2.2 mg/h | Transdermal | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| METHYLPHENIDATE 3.3 mg/h | Transdermal | Mylan Pharmaceuticals Inc. | ANDA | View NDC → |
| METHYLPHENIDATE 10 mg/9h | Transdermal | Noven Therapeutics, LLC | NDA | View NDC → |
| METHYLPHENIDATE 15 mg/9h | Transdermal | Noven Therapeutics, LLC | NDA | View NDC → |
| METHYLPHENIDATE 20 mg/9h | Transdermal | Noven Therapeutics, LLC | NDA | View NDC → |
| METHYLPHENIDATE 30 mg/9h | Transdermal | Noven Therapeutics, LLC | NDA | View NDC → |
| 27.5 mg/mg | Transdermal | Padagis Us Llc | NDA AUTHORIZED GENERIC | View NDC → |
| 41.3 mg/mg | Transdermal | Padagis Us Llc | NDA AUTHORIZED GENERIC | View NDC → |
| 55 mg/mg | Transdermal | Padagis Us Llc | NDA AUTHORIZED GENERIC | View NDC → |
| 82.5 mg/mg | Transdermal | Padagis Us Llc | NDA AUTHORIZED GENERIC | View NDC → |
| 💊Tablet | ||||
| 5 mg | Oral | Accord Healthcare, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Accord Healthcare, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Accord Healthcare, Inc. | ANDA | View NDC → |
| 5 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 10 mg | Oral | American Health Packaging | ANDA | View NDC → |
| 5 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 10 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 20 mg | Oral | Amneal Pharmaceuticals of New York LLC | ANDA | View NDC → |
| 5 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 10 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 20 mg | Oral | Ascend Laboratories, LLC | ANDA | View NDC → |
| 5 mg | Oral | Aurolife Pharma, LLC | ANDA | View NDC → |
| 10 mg | Oral | Aurolife Pharma, LLC | ANDA | View NDC → |
| 20 mg | Oral | Aurolife Pharma, LLC | ANDA | View NDC → |
| 5 mg | Oral | Bryant Ranch Prepack × 4 listings | ANDA | View NDC → |
| 5 mg | Oral | Camber Pharmaceutical Inc | ANDA | View NDC → |
| 10 mg | Oral | Camber Pharmaceutical Inc | ANDA | View NDC → |
| 20 mg | Oral | Camber Pharmaceutical Inc | ANDA | View NDC → |
| 5 mg | Oral | Kvk-tech, Inc. | ANDA | View NDC → |
| 10 mg | Oral | KVK-Tech, Inc. × 2 listings | ANDA | View NDC → |
| 5 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 10 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 20 mg | Oral | Lupin Pharmaceuticals,Inc. | ANDA | View NDC → |
| 5 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Nivagen Pharmaceuticals, Inc. | ANDA | View NDC → |
| 5 mg | Oral | Sandoz Inc | NDA | View NDC → |
| 10 mg | Oral | Sandoz Inc | NDA | View NDC → |
| 20 mg | Oral | Sandoz Inc | NDA | View NDC → |
| 5 mg | Oral | Solco Healthcare US,LLC | ANDA | View NDC → |
| 10 mg | Oral | Solco Healthcare US,LLC | ANDA | View NDC → |
| 20 mg | Oral | Solco Healthcare US,LLC | ANDA | View NDC → |
| 5 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 10 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 20 mg | Oral | SpecGx LLC | ANDA | View NDC → |
| 5 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 10 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 20 mg | Oral | Sun Pharmaceutical Industries, Inc. | ANDA | View NDC → |
| 5 mg | Oral | XLCare Pharmaceuticals Inc | ANDA | View NDC → |
| 10 mg | Oral | XLCare Pharmaceuticals Inc | ANDA | View NDC → |
| 20 mg | Oral | XLCare Pharmaceuticals Inc | ANDA | View NDC → |
Showing 200 of 246 products — FDA National Drug Code Directory. See every product, package size and price: browse all 246 Methylphenidate NDCs →
Methylphenidate side effects reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Methylphenidate — a signal of what to watch for, not proof the drug caused it.
The effects most often named in FDA reports that mention Methylphenidate are product quality issue, fatigue, headache; about 51% of the reports were classed as serious. These are voluntary reports, so they show what people report, not how often it happens.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Methylphenidate in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Methylphenidate FDA approval history
How Methylphenidate went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Methylphenidate was first approved by the FDA in 1955 (Brand: RITALIN · Sandoz); the first generic version was approved in 1977. It remains available in U.S. pharmacies today.
Source: Drugs@FDA.
Methylphenidate recall history
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list 7 Methylphenidate recalls since July 2021, covering 10 product listings. Five of them are still ongoing or began in the last six months and are listed first. A recall names specific lots from one company, so check the lot number on your own bottle rather than assuming every product is affected; your pharmacist can check whether your supply came from an affected lot.
- Daytrana (methylphenidate transdermal system) CII, 30 mg, 30-count carton, Rx only, Manufactured for Noven Therapeutics, LLC., Miami by Noven Pharmaceuticals, Inc., NDC 68968-5555-3 Lots: Lot#: 91474, 91959, Exp. 3/2023; 91958, Exp. 6/2023; 92478, Exp. 7/2023; 92479 & 92198, Exp. 8/2023; 92199, 93040, Exp. 9/2023; 93041, Exp. 10/2023. FDA record D-0473-2023 →
- Daytrana (methylphenidate transdermal system) CII, 20mg, 30-count carton, Rx only, Manufactured for Noven Therapeutics, LLC., Miami by Noven Pharmaceuticals, Inc., NDC 68968-5554-3. Lots: Lot#: 91957, 92197, Exp. 7/2023; 92476, Exp. 9/2023; 92477, Exp. 10/2023 FDA record D-0472-2023 →
- Daytrana (methylphenidate transdermal system) CII, 15 mg, 30-count carton, Rx only, Manufactured for Noven Therapeutics, LLC., Miami by Noven Pharmaceuticals, Inc., NDC 68968-5553-3 Lots: Lot#: 91956, Exp. 6/2023; 92475, Exp. 7/2023 FDA record D-0471-2023 →
- Daytrana (methylphenidate transdermal system) CII, 10mg, 30-count carton, Rx only, Manufactured for Noven Therapeutics, LLC., Miami by Noven Pharmaceuticals, Inc., NDC 68968-5552-3. Lots: Lot#: 91955, Exp. 7/2023; 93039, Exp. 10/2023 FDA record D-0470-2023 →
- Daytrana (methylphenidate transdermal system), Delivers 15 mg over 9 hours, (1.6 mg/hr), 30 patches per box, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186; By Noven Pharmaceutica… Lots: Lot: 91316 Exp. 02/2023 FDA record D-0071-2023 →
- Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Contains: 30 Patches, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186 By Noven Pharmaceuticals… Lots: Lot: 91272 Exp. 12/22. FDA record D-1169-2022 →
- Daytrana (methylphenidate transdermal system) Delivers 10 mg over 9 hours (1.1 mg/hr) Contains: 30 Patches, Rx only, Manufactured for Noven Therapeutics, LLC, Miami, FL 33186, By Noven Pharmaceutical… Lots: Lot: 90764 Exp. 08/2022 FDA record D-0889-2022 →
- Methylphenidate Hydrochloride Chewable Tablets, 2.5 mg, 100-count bottle, Rx Only, Manufactured for: Rising Pharmaceuticals Inc., Saddle Brook, NJ 07863, NDC 64980-221-01 Lots: lot# 25910009, Exp 01/2023 FDA record D-0573-2022 →
- Methylphenidate Hydrochloride, Extended-release Tablets, USP, 36mg, 100-count Bottle, Rx Only, Manufactured for: Trigen Laboratories, LLC, Alpharetta, GA 30005, NDC 13811-708-10 Lots: Lot 230159M, Exp Date 2/28/2026 FDA record D-0579-2024 →
- Methylphenidate Hydrochloride Tablets, USP 20mg, Rx Only, 100 Tablets per bottle, Manufactured by: Ohm Laboratories Inc., New Brunswick, NJ 08901, Distributed by: Sun Pharmaceutical Industries Inc.,… Lots: Lot AC74459, Exp 07/31/2024 FDA record D-0940-2023 →
Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Sep 24, 2026.
RxNorm Concept Web — From Ingredient to Every Form and Strength
This page starts with one ingredient concept (IN). The branches below show its dose-form concepts (SCDF), then the available clinical drug and strength concepts (SCD). Combination products remain separate concepts with their own pages.
RxCUI 6901 9 dose forms · 56 strengths
-
Dose form (SCDF) Chewable Extended Release Oral Tablet RxCUI 2270756In current FDA listingsClinical drug / strength (SCD) 24 HR methylphenidate hydrochloride 20 MGRxCUI 172744324 HR methylphenidate hydrochloride 30 MGRxCUI 173492824 HR methylphenidate hydrochloride 40 MGRxCUI 1734951 -
Dose form (SCDF) Chewable Tablet RxCUI 476365In current FDA listingsClinical drug / strength (SCD) hydrochloride 10 MGRxCUI 1091152hydrochloride 2.5 MGRxCUI 1091389hydrochloride 5 MGRxCUI 1091322 -
Dose form (SCDF) Disintegrating Oral Tablet RxCUI 1926839In current FDA listings -
Dose form (SCDF) Extended Release Oral Capsule RxCUI 374655In current FDA listingsClinical drug / strength (SCD) Evening Dosing 24 HR methylphenidate hydrochloride 100 MGRxCUI 2168864Evening Dosing 24 HR methylphenidate hydrochloride 20 MGRxCUI 2168866Evening Dosing 24 HR methylphenidate hydrochloride 40 MGRxCUI 2168868Evening Dosing 24 HR methylphenidate hydrochloride 60 MGRxCUI 2168857Evening Dosing 24 HR methylphenidate hydrochloride 80 MGRxCUI 216886130/70 Release 24 HR methylphenidate hydrochloride 10 MGRxCUI 180618130/70 Release 24 HR methylphenidate hydrochloride 20 MGRxCUI 180618730/70 Release 24 HR methylphenidate hydrochloride 30 MGRxCUI 180618930/70 Release 24 HR methylphenidate hydrochloride 40 MGRxCUI 180619130/70 Release 24 HR methylphenidate hydrochloride 50 MGRxCUI 180619330/70 Release 24 HR methylphenidate hydrochloride 60 MGRxCUI 180619740/60 Release 24 HR methylphenidate hydrochloride 10 MGRxCUI 180620040/60 Release 24 HR methylphenidate hydrochloride 15 MGRxCUI 164818340/60 Release 24 HR methylphenidate hydrochloride 20 MGRxCUI 180620240/60 Release 24 HR methylphenidate hydrochloride 30 MGRxCUI 180620640/60 Release 24 HR methylphenidate hydrochloride 40 MGRxCUI 180621040/60 Release 24 HR methylphenidate hydrochloride 50 MGRxCUI 180620440/60 Release 24 HR methylphenidate hydrochloride 60 MGRxCUI 180620850/50 Release 24 HR methylphenidate hydrochloride 10 MGRxCUI 180619550/50 Release 24 HR methylphenidate hydrochloride 20 MGRxCUI 180617750/50 Release 24 HR methylphenidate hydrochloride 30 MGRxCUI 180617950/50 Release 24 HR methylphenidate hydrochloride 40 MGRxCUI 180618350/50 Release 24 HR methylphenidate hydrochloride 60 MGRxCUI 1806185 -
Dose form (SCDF) Extended Release Oral Tablet RxCUI 372862In current FDA listingsClinical drug / strength (SCD) BX Rating 24 HR methylphenidate hydrochloride 18 MGRxCUI 2001564BX Rating 24 HR methylphenidate hydrochloride 27 MGRxCUI 2001565BX Rating 24 HR methylphenidate hydrochloride 36 MGRxCUI 2001566BX Rating 24 HR methylphenidate hydrochloride 54 MGRxCUI 20015688 HR methylphenidate hydrochloride 10 MGRxCUI 10911458 HR methylphenidate hydrochloride 20 MGRxCUI 109122524 HR methylphenidate hydrochloride 18 MGRxCUI 109115524 HR methylphenidate hydrochloride 27 MGRxCUI 109117024 HR methylphenidate hydrochloride 36 MGRxCUI 109118524 HR methylphenidate hydrochloride 45 MGRxCUI 260579824 HR methylphenidate hydrochloride 54 MGRxCUI 109121024 HR methylphenidate hydrochloride 63 MGRxCUI 260579624 HR methylphenidate hydrochloride 72 MGRxCUI 1995461 -
Dose form (SCDF) Extended Release Suspension RxCUI 1312582In current FDA listingsClinical drug / strength (SCD) 24 HR methylphenidate hydrochloride 5 MG/MLRxCUI 1312583 -
Dose form (SCDF) Oral Solution RxCUI 476368In current FDA listingsClinical drug / strength (SCD) hydrochloride 1 MG/MLRxCUI 1091341hydrochloride 2 MG/MLRxCUI 1091133 -
Dose form (SCDF) Oral Tablet RxCUI 372861In current FDA listingsClinical drug / strength (SCD) hydrochloride 10 MGRxCUI 1091150hydrochloride 2.5 MGRxCUI 1091501hydrochloride 20 MGRxCUI 1091392hydrochloride 5 MGRxCUI 1091497 -
Dose form (SCDF) Transdermal System RxCUI 1805912In current FDA listingsClinical drug / strength (SCD) 9 HR methylphenidate 1.11 MG/HRRxCUI 7534369 HR methylphenidate 1.67 MG/HRRxCUI 7534389 HR methylphenidate 2.22 MG/HRRxCUI 7534409 HR methylphenidate 3.33 MG/HRRxCUI 753441
Look up RxCUI 6901 in the RxCUI Atlas →
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Methylphenidate supply and shortage status
Whether Methylphenidate is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Methylphenidate is currently listed in shortage by the FDA (10 presentations on record).
⚠️Currently in shortage (FDA) — MethylphenidateSource: openFDA, from the FDA Drug Shortages database.
💵 What Methylphenidate costs pharmacies (NADAC benchmark)
The national average invoice price pharmacies pay for the drug itself, from CMS's NADAC survey (data as of Sep 30, 2026). This is a supply-cost benchmark — not a retail price and not what you'd pay at the counter.
| Form | Strength | Pharmacy acquisition benchmark | |
|---|---|---|---|
| Capsule, Extended Release · Oral | 20 mg | $12.10 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | 30 mg | $12.39 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | 40 mg | $12.73 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | 10 mg | $12.07 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | 60 mg | $1.80 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | 50 mg | $1.57 per capsule | NDC details & price history |
| Capsule, Extended Release · Oral | 15 mg | $2.65 per capsule | NDC details & price history |
| Tablet, Extended Release · Oral | 36 mg | $0.672 per tablet | NDC details & price history |
| Tablet, Extended Release · Oral | 27 mg | $0.677 per tablet | NDC details & price history |
| Tablet, Extended Release · Oral | 54 mg | $0.805 per tablet | NDC details & price history |
Source: CMS National Average Drug Acquisition Cost (NADAC), a survey of retail pharmacy invoice prices. Benchmarks shown are the range across package sizes of a representative product for each form and strength — other manufacturers' products may differ.
Methylphenidate brand names
Methylphenidate is sold under 16 brand names in the FDA directory — Adhansia XR, Aptensio XR, Concerta, Cotempla XR-ODT and others. A brand and its generic contain the same active ingredient; the brand name belongs to one company's product.
Who makes Methylphenidate: manufacturers and labelers
43 companies list Methylphenidate products with the FDA. By number of product records, the largest are Bryant Ranch Prepack, Lannett Company, Inc., SpecGx LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
…and 19 more on the FDA NDC directory.
Methylphenidate drug class (RxNorm)
Methylphenidate belongs to the Central Nervous System Stimulant class.
Classified by RxNorm RxClass — the U.S. National Library of Medicine's standardized drug-classification service (Established Pharmacologic Class from the FDA, the ATC drug family from the WHO, and mechanism of action). Reference only, not medical advice.
Sources for this Methylphenidate page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Sandoz Inc is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →